NDV-01 — Initial data
YE 2026
Initial 3-month NDV-01 data from Phase 3 2L BCG-unresponsive study – YE 2026Source filing
RLMD biotech catalysts & pipeline
RELMADA THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
NDV-01 — IND submission
Late 2026
NDV-01 United States IND filing with the FDA by year-end 2026Source filing
NDV-01 — NDA/BLA submission
Late 2026
● NDV-01 United States IND filing with the FDA by year-end 2026Source filing
sepranolone — IND submission
Late 2026
Sepranolone – United States IND filing with the FDA by year-end 2026Source filing
sepranolone — NDA/BLA submission
Late 2026
● Sepranolone – United States IND filing with the FDA by year-end 2026Source filing